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Abstract: Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory
documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim was
to assess the potential usefulness of viscoelastometric testing (VET) to predict thrombotic events
in COVID-19 patients according to the literature. We also (i) analyzed the impact of anticoagula-
tion and the methods used to neutralize heparin, (ii) analyzed whether maximal clot mechanical
strength brings more information than Clauss fibrinogen, and (iii) critically scrutinized the diagnosis
of hypofibrinolysis. We performed a systematic search in PubMed and Scopus databases until
31 December 2020. VET methods and parameters, and patients’ features and outcomes were ex-
tracted. VET was performed for 1063 patients (893 intensive care unit (ICU) and 170 non-ICU, 44
studies). There was extensive heterogeneity concerning study design, VET device used (ROTEM,
TEG, Quantra and ClotPro) and reagents (with non-systematic use of heparin neutralization), timing
of assay, and definition of hypercoagulable state. Notably, only 4 out of 25 studies using ROTEM
reported data with heparinase (HEPTEM). The common findings were increased clot mechanical
strength mainly due to excessive fibrinogen component and impaired to absent fibrinolysis, more
conspicuous in the presence of an added plasminogen activator. Only 4 studies out of the 16 that
addressed the point found an association of VETs with thrombotic events. So-called functional
fibrinogen assessed by VETs showed a variable correlation with Clauss fibrinogen. Abnormal VET
pattern, often evidenced despite standard prophylactic anticoagulation, tended to normalize after
increased dosing. VET studies reported heterogeneity, and small sample sizes do not support an
association between the poorly defined prothrombotic phenotype of COVID-19 and thrombotic
events.
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1. Introduction
In contrast to conventional clotting tests, viscoelastic tests (VETs) monitor changes
of viscoelastic properties of a forming and evolving clot from whole blood, before and
beyond the clotting point; they are often referred to as a global hemostasis test, although
some aspects of hemostasis are not explored [1–3]. Coagulation occurs in the presence of
platelets and red blood cells, and fibrinolysis can translate into a decrease in clot mechanical
strength after its maximum has been reached, but clot retraction seems to play a role here
as well [4–6]. VETs are based on the mechanical properties of the clot, like mechanical
strength, and are influenced by its composition in platelets, fibrin, red blood cells, and
factor XIII [7–9]. To our knowledge, the assessment of factor XIII by VETs has not been
investigated in COVID-19 patients.
VETs have been considered to provide a comprehensive assessment of the dynamic
process of blood clot formation and subsequent lysis. As they can be performed bedside
as point-of-care testing and can give useable results about clot formation and a potential
hyperfibrinolysis within one hour, they are chiefly considered as convenient tools for real-
time assessment of coagulation and fibrinolysis in whole blood and have been gaining in
popularity in various hemorrhagic situations, such as cardiac surgery, obstetrics, and trau-
matology over decades, for the management of acutely bleeding patients [3]. By contrast,
COVID-19 disturbance of hemostasis is likely a combination of hypercoagulability and
impaired fibrinolysis (a prothrombotic laboratory phenotype), at least in part, contributing
to the thrombotic risk and the prothrombotic laboratory phenotype, but VETs have been
nevertheless suggested to be potentially useful, in line with previous works on sepsis [10]
and trauma [11,12], for example.
Of note, VETs share the same limitations as all currently available clinical lab tests, i.e.,
negligible effect of endogenous anticoagulants, absence of endothelium, and very low shear
in a close system. Furthermore, there are good reasons to challenge the interpretation of
hypercoagulability and to question the ability to sensitively detect and accurately quantify
hypofibrinolysis, especially when a value equal to zero belongs to the manufacturer’s
reference range.
Our aim was to assess the potential clinical usefulness of VETs to predict clinical
outcomes (mainly thrombotic events) in COVID-19 patients through this systematic review.
We also (i) analyzed the impact of anticoagulation and the methods used to neutralize hep-
arin (in other words, was heparin duly neutralized?), (ii) disentangled reported alterations
in clotting dynamics and analyzed whether maximal clot mechanical strength brings more
information than Clauss fibrinogen, and (iii) critically scrutinized the documentation of
hypofibrinolysis with VET under various reactive conditions. The term ‘hypercoagulable
state’ will be uniformly used to refer to the investigators’ interpretation of VET findings;
we will discuss to what extent this is an appropriate interpretation.
The preanalytical aspects, which are crucial in laboratory hemostasis but scarcely
mentioned among the retrieved studies, are beyond the scope of this review and will not
be addressed.
2. Materials and Methods
2.1. Search Methodology
We performed a systematic literature search in PubMed and Scopus databases, regard-
less of publication status, using the following keywords ‘viscoelastic test OR thromboelas-
tometry OR thromboelastography OR sonorheometry OR ROTEM OR TEG OR Quantra
OR ClotPro’ AND ‘coronavirus disease 2019 OR COVID-19 OR severe acute respiratory
J. Clin. Med. 2021, 10, 1740 3 of 56
syndrome coronavirus 2 OR SARS-CoV-2’. Search strategy is provided as Data S1. We
also searched the reference lists of selected articles for additional relevant works, and
we did not restrict our search to articles published in English and found some articles in
Russian and Hungarian. In addition, reviewers performed manual searches and cross-
references in the retrieved papers. The last search was conducted on 31 December 2020.
Our review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-analysis) guidelines [13], and the PRISMA summary table can be found as Data S2.
Due to a considerable heterogeneity among the retrieved studies, we did not extend our
systematic review to a meta-analysis.
2.2. Study Selection
All references retrieved from our search were screened based upon their title and
abstract to assess eligibility. If they were considered relevant, the full-text articles were
analyzed to check if they met the selection criteria as follows. As COVID-19 pandemic
is a recent phenomenon, and due to the relatively small number of published data on
VETs, we did not restrict eligibility according to patients’ characteristics, disease severity,
or treatment modalities. Studies of any design and case reports, including original data
from VETs in COVID-19 patients with neither pregnancy nor known history of coagulation
disorder, were deemed eligible. All relevant studies regardless of methodological quality
were included when the full-text article was available (Table 1).
Table 1. Eligibility criteria.
PICOS Inclusion Exclusion
Participants All patients with confirmed COVID-19 infection regardless of age PregnancyPre-existing coagulation disorder
Intervention Viscoelastometric testing performed -
Comparison
Reference values (manufacturer’s based or healthy controls)
ICU COVID-19 patients and non-ICU COVID-19 patients
ICU COVID-19 patients and ICU non-COVID-19 patients
-
Outcomes
VET parameters in COVID-19 patients
Difference in VET parameters between ICU COVID-19 patients and
non-ICU COVID-19 patients
Difference in VET parameters between ICU COVID-19 patients and
ICU non-COVID-19 patients
Association between VET parameters and clinical
outcomes











Non-human or in vitro studies
Abbreviations: VET: viscoelastometric testing; ICU: Intensive care unit.
Reviews, position articles, and guidelines were excluded. All kind of VETs were
included but were analyzed separately.
2.3. Data Extraction
For each study, data regarding author identification, geographic location, study design,
number of patients and their characteristics (including comorbidities and thrombotic
events), prospective design or not, timing of blood collection and anticoagulation status,
type of VET device used and results, and the results of other conventional hemostasis
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tests (platelet count, fibrinogen and D-dimers plasma levels), and C-reactive protein were
extracted with the aid of a systematic chart.
2.4. A Concise Overview of the Different VET Devices
Viscoelastometric testing (VET) should be performed either immediately with native
whole blood or within four hours after drawing if performed with whole citrated blood, as
most often done [1,3].
ROTEM devices and TEG5000 all rely on the movement of a pin and a cup relative
to each other; in the former, the cuvette is fixed, and the pin oscillates, and vice versa in
the latter. The oscillations are recorded and graphically displayed with the characteristic
normal tuning fork shape [3]. The conventional clotting point roughly corresponds to the
reaction time R for TEG, and to the clotting time CT for ROTEM, ClotPro, and Quantra;
extended fibrin polymerization is monitored with the kinetics time K and α angle for
TEG and with CFT and α angle for ROTEM and ClotPro; the eventual result is maximal
mechanical strength (maximal amplitude MA for TEG, maximal clot firmness MCF for
ROTEM and ClotPro and clot stiffness CS for Quantra) and its subsequent decrease, as a
result of ‘endogenous’ fibrinolysis monitored by lysis of the clot at given time x LY(x) for
TEG and by maximal lysis ML or lysis of the clot at a given time x (LI(x)) for ROTEM and
ClotPro, at least in part [2,3,14].
Coagulation can be initiated through the contact phase or the tissue factor pathway
(often referred to as intrinsic or extrinsic pathways, respectively) and needs recalcifica-
tion when citrated blood is used [3]. If the nature of the initiating agents is known, their
concentrations are not disclosed. Regarding the former pathway, the limitations of aPTT
testing apply, although ‘clotting times’ are longer, suggesting a lower amount of contact
phase activator (kaolin, celite, or ellagic acid) and higher calcium concentration. The differ-
ent well-known behaviors of those reagents in case of defective contact phase, abnormal
factor VIII levels, high CRP (C-reactive protein) levels, lupus anticoagulant, or heparin
must be borne in mind. Two reagents can be used to neutralize heparin, either polybrene
(hexadimethrine bromide) or heparinase; two to inhibit the platelet contribution to me-
chanical clot properties, namely cytochalasin D and abciximab, sometimes both together;
lastly, two to inhibit fibrinolysis, either aprotinin or tranexamic acid [3]. To what extent
those inhibitions are fully achieved is not entirely clear.
2.4.1. ROTEM
Three versions of the ROTEM device exist: from the oldest to the most recent, ROTEM-
gamma, ROTEM-delta, and the brand-new version ROTEM-sigma. The main difference
between them is that ROTEM-gamma and -delta need manual pipetting of the blood
sample and the reagents into cups, whereas ROTEM-sigma is a completely automated,
closed system. For the latter, reagents consist of a consumable ready-to-use cartridge
with four parallel channels prefilled with specific lyophilized reagents [15]. All ROTEM
versions can perform the same assays, namely INTEM, HEPTEM, EXTEM, FIBTEM, and
APTEM, to investigate the intrinsic pathway (with and without heparinase), the extrinsic
pathway, the fibrinogen component, and the fibrinolysis with aprotinin, respectively. Of
note, EXTEM, FIBTEM, and APTEM reagents contain polybrene and HEPTEM contain
heparinase to neutralize heparin (Table A1) [2,16]. They report the same parameters:
clotting time (CT), clot formation time (CFT), α angle, “amplitude of the clot” at a given
time x (A(x)), maximum clot firmness (MCF), clot lysis index (LI(x)), and maximum lysis
(ML) (Table A2).
2.4.2. TEG
Briefly, regarding TEG5000 a blood sample is pipetted into a cup; liquid reagents are
added; ultimately, a fixed pin connected to a detector system is then put in the cup. The
graphical representation is called TEMogram. TEG6s for its part is a completely closed
and automated system. In contrast to its predecessor TEG5000, it relies on sonorheometry.
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Reagents consist of a consumable, ready-to-use cartridge with four parallel channels
prefilled with specific lyophilized reagents (Table A3) [17,18].
The two versions of the TEG device can perform the same assays, namely Kaolin
TEG with (CKH) or without heparinase (CK), RapidTEG (CRT), and TEG Functional
Fibrinogen (CFF), and offer the same parameters: reaction time (R), kinetics time (K), α
angle, maximum amplitude (MA), and fibrinolytic activity (Ly) [3,19]. Of note, heparin
neutralization differs between TEG500, where neutralization can occur in virtually any
channel by using heparinase-coated cups, and TEG6s, where neutralization occurs only in
the CKH channel thanks to heparinase (Table A4) [3].
2.4.3. Quantra
The Quantra device also uses sonorheometry. Briefly, an acoustic radiation force is
applied to the blood sample. As the blood clot forms, it starts to resonate: oscillations are
then correlated with the shear modulus of the blood sample. The resistance of the sample
to shear forces can be quantified by the time delay between the ultrasound pulse emission
and the returning echoes [20–22].
Reagents consist of a consumable, ready-to-use cartridge with four parallel channels
prefilled with specific lyophilized reagents [22]. There are currently two kinds of cartridges:
the QPlus cartridge and the QStat one dedicated to exploring fibrinolysis [23]. Measure-
ments of clot coagulation time with (CTH) or without (CT) heparinase and coagulation
initiation with kaolin, clot stiffness (CS) after initiation with thromboplastin, and fibrinogen
contribution to the overall clot stiffness (FCS) after platelet inhibition with abciximab are
performed simultaneously in four parallel channels. Of note, channel 2 contains heparinase,
and channels 3 and 4 contain polybrene to neutralize heparin. Platelet contribution to clot
stiffness (PCS) results from the difference between total CS and FCS (Tables A5 and A6).
2.4.4. ClotPro
The ClotPro device uses rotational technology similar to ROTEM®(Werfen, Barcelona,
Spain), but some differences exist between the two devices. First, in contrast with ROTEM,
the cuvette rotates and the pin is stationary [24,25]. Second, reagents for each assay are
present in dry form in a sponge located in the pipette tip; during pipetting of the patient
sample, the reagent is automatically added to the blood [25]. This device can perform the
same kind of assays as the ROTEM device (EX-test, IN-test, HI-test, FIB-test, AP-test) plus
some other specific ones (RVV-test, ECA-test), and offer similar parameters. Of note, EX-
test, tPA-test, and FIB-test contain polybrene to neutralize heparin (Tables A7 and A8) [24].
3. Results
3.1. Literature Search
Our literature search and selection flow chart according to PRISMA statement [13] is
summarized in Figure 1.
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clusion, and the full-text articles were retrieved. The most common reasons for exclusion 
after the full-text evaluation were that papers were reviews (n = 19), not related to the 
subject (n = 6), or position articles or guidelines (n = 4). Finally, 44 references [24,26–68] 
met the eligibility criteria.  
3.2. Originality of Our Systematic Review as Compared to the Existing Ones on the Subject 
Reviews have already been published recently, two of them only being systematic 
[69–72], but none has so far investigated the four major commercially available VET de-
vices (i.e., ROTEM, TEG, ClotPro, and Quantra) or included such a large number of 
studies (n = 44). Characteristics of each review are summarized in Table 2. 
Overall, case reports were excluded (except for one systematic review [71]); few 
studies were available and presented extensive heterogeneity. 
  
. l ti fl c rt cc r i g to IS state ent.
e identified 140 references, resulting in 97 unique citations after duplicates removal.
Two additional articles were identified through other sources. Each title and abstract
were screened, and 36 references were excluded either because they were not related to
the subject (n = 16), because they were position articles or guidelines (n = 7) or reviews
(n = 5), or because there was no full-text available at this time (n = 5) or no possible
translation (n = 5). A total of 63 potentially eligible articles were considered for inclusion,
and the full-text articles were retrieved. The most common reasons for exclusion after
the full-text evaluation were that papers were reviews (n = 19), not related to the subject
(n = 6), or position articles or guidelines (n = 4). Finally, 44 references [24,26–68] met the
eligibility criteria.
3.2. Originality of Our Systematic Review as Compared to the Existing Ones on the Subject
Reviews have already been published recently, two of them only being system-
atic [69–72], but none has so far investigated the four major commercially available VET
devices (i.e., ROTEM, TEG, ClotPro, and Quantra) or included such a large number of
studies (n = 44). Characteristics of each review are summarized in Table 2.
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Table 2. Characteristics of the reviews already published.
First Author (Title) Type of the Review Aim of the Review Number and Type ofStudies Included VET Devices




what do we know already









8 studies (5 prospective,
3 retrospective) ROTEM, TEG, Quantra





Paradigm for Their Clinical
Utility in Critical Illness)
Narrative review
Evaluation of the









Hartmann et al. [71]





































Overall, case reports were excluded (except for one systematic review [71]); few
studies were available and presented extensive heterogeneity.
3.3. Characteristics of the Selected Studies
Quality assessment of the selected study was performed using the Scottish Intercolle-
giate Guidelines Network (SIGN) grading system [73]. Overall, the retrieved studies were
of low (3, “non analytic studies”) to moderate quality (2+, “well-conducted case control or
cohort studies with a low risk of confounding or bias and a moderate probability that the
relationship is causal”), and details can be found as Data S3. Characteristics of the selected
studies are summarized in Table 3.
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Table 3. Characteristics of the included studies.
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A total of 1538 inpatients were studied, of which 1393 were COVID-19-positive, among
whom 1189 were ICU patients. At least one VET was performed during the hospital stay
of 1208 patients, of whom 1063 were COVID-19 patients hospitalized either in an ICU
(893 patients) or in a medical ward (IMW, 170 patients). The remaining 145 patients were
sex- and age-matched non-COVID-19 controls hospitalized either in the ICU (89 patients)
or in IMW (56 patients) for ARDS (acute respiratory distress syndrome) or pneumonia
non-related to SARS-CoV-2, or for postoperative care. One article [33] reported data about
eight hospitalized children either in a pediatric ward or in a pediatric ICU (PICU).
Among the 44 retrieved studies, 19 were prospective [28–32,39–46,52,59–61,66,67], 18
were retrospective [24,27,33–36,48,49,51,53–58,62–64], one was a cross-sectional study [47],
and six were case reports [26,37,38,50,65,68]. There was no randomized controlled trial
(VET versus no VET).
VETs were performed using ROTEM (25 studies), TEG (15 studies), Quantra (two
prospective studies [66,67]) and ClotPro (one retrospective study [24] and one case re-
port [68]); no study compared two devices. Among articles reporting data about TEG, four
were prospective studies [52,59–61], ten were retrospective studies [51,53–58,62–64], and
one was a case report [65]. Among articles dealing with ROTEM, thirteen were prospec-
tive studies [28–32,39–46], seven were retrospective studies [27,33–36,48,49], one was a
cross-sectional study [47], and four were case reports [26,37,38,50].
Testing was carried out either on admission or within the following days, but the
timing of blood collection for VET was specified only for 29 studies [24,26,27,29–31,33,35–
38,41,43–48,50,53,55–59,65–67]. In some studies, the measurements were repeated during
the patient’s stay, either because of a pre-established protocol [26,27,29,45,53,59,60,67] or
because of the occurrence of a thromboembolic event [65,68]. Number of VETs performed
during a patient’s stay ranged from 1 to 5 [29].
3.4. Characteristics of the Included Patients
Characteristics of the included patients are shown in Table 4.
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Table 4. Characteristics of the included patients.
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Table 4. Cont.
First Author



























































(42–58) 12 M: 5 F 12 (9–17) NP
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COVID- 34(28–55) 7 M: 4 F 9 (7–17) NP
57












(Italy) [67] Quantra 16 ICU
61


































62 M NP NP NP NP NP NP NP
Yes 2
21 NP NP NP
1 80 M NP NP NP NP NP NP NP 176–221 448 7370 NP
1 84 F NP NP NP NP NP NP NP 230–376 544 10,600 NP
Values in italics and in brackets are the reference values; we have indicated our reference ranges * for information purposes. Comorbidities: 1 Overweight and obesity, associated with high blood pressure,
diabetes and cardiovascular risk factors; 2 High blood pressure, diabetes and some additional comorbidities; 3 Overweight and obesity, with some additional comorbidities; 4 Overweight and obesity; 5
Overweight and obesity, associated with high blood pressure, diabetes, pulmonary disease and cardiovascular risk factors; 6 Overweight and obesity, associated with high blood pressure; 7 Overweight and
obesity, associated with cardiovascular risk factors, pulmonary disease and kidney disease; 8 Overweight and obesity, associated with diabetes, cardiovascular risk factors, pulmonary disease and kidney disease;
9 Overweight and obesity, associated with high blood pressure, diabetes, kidney disease and cardiovascular risk factors; 10 Overweight and obesity, associated with high blood pressure, diabetes, pulmonary
disease, kidney disease and cardiovascular risk factors; 11 Overweight and obesity, associated with high blood pressure and diabetes. Abbreviations: ICU: Intensive care unit (adults); IMW: Internal medicine
ward; PICU: Pediatric intensive care unit; PW: Pediatric ward; IMV: Invasive mechanical ventilation; ECMO: Extracorporeal membrane oxygenation; RRT: Renal replacement therapy; M: Male; F: Female; SOFA
score: Sequential organ failure assessment score; APACHE score: Acute physiology and chronic health evaluation score; SAPS score: Simplified acute physiology score; DIC score: Disseminated intravascular
coagulation score; SIC score: Sepsis-induced coagulopathy score; BMI: Body mass index; CRP: C-reactive protein; NP: Not provided; TEG: Thromboelastography; ROTEM: Rotational thromboelastometry; TEM:
Thromboelastometry; tPA: tissue plasminogen activator.
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The number of COVID-19 patients with at least one VET performed in each article
ranged from 1 [26,38,65] to 64 [58]. Mean or median adult COVID-19 patients ages ranged
from 39 [65] to 84 years [68]. Excluding case reports, the proportion of women among the
studies reporting gender ranged from 0 [40] to 50% [29,33,36].
Overall, most patients presented with overweight or obesity, associated with other ad-
ditional co-morbidities such as diabetes or hypertension. Overall, COVID-19 patients were
characterized by hyperfibrinogenemia, marked increased D-dimer levels, and increased
C-reactive protein (CRP). The majority of patients received thromboprophylaxis either
with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) (at usual
prophylactic doses or higher) according to published guidance [74–76] or local protocols.
Thrombotic events (such as deep vein thrombosis, pulmonary embolism, ischemic stroke,
or acute kidney injury) were reported as an outcome in 36 articles [24,26–29,31,33,34,36–
40,42–44,47–49,51,53–68].
3.5. Results of the Viscoelastic Tests
3.5.1. ROTEM
ROTEM devices were used in 25 studies with a total of 708 patients, of whom 435
were ICU COVID-19 patients, most of them intubated and mechanically ventilated. Five
studies compared results from COVID-19 patients versus non COVID-19 patients: one
reported data from non-ICU patients [46], whereas the four other ones reported data from
ICU patients [32,35,36,45]. Six studies reported data from both ICU and IMW COVID-19
patients [28,32,33,39,41,48].
Data from ROTEM gamma, delta, and sigma were reported in one study, thirteen
studies [28–40], and ten [41–50], respectively. One case report did not specify the device [26].
Results are displayed in Table 5 (EXTEM, INTEM, and FIBTEM assays), Table 6 (INTEM
and HEPTEM assays), and Table 7 (EXTEM and TEP-tPA).
As a general rule, three assays were performed, mostly INTEM (19 studies), EXTEM
(23 studies), and FIBTEM (23 studies). The great majority of the articles reported results
from EXTEM assay with or without INTEM assay and associated with FIBTEM assay.
Only four articles [26,41,44,50] reported data from HEPTEM assay (Table 6), while almost
all patients received anticoagulation by UFH or LMWH at least at a prophylactic dose.
The APTEM assay results were only reported by one case report [26] and were consistent
with the absence of hyperfibrinolysis. Two studies reported data from TEM-tPA (Table 7),
an investigator-modified assay derived from EXTEM assay to investigate a potential
hypofibrinolysis [39,40].
Among the 18 articles reporting data from EXTEM, INTEM, and FIBTEM assays,
16 [26,27,29,31,33,36,38,41,42,44–50] found an increase in “amplitude of the clot” in the
three assays, and 2 only in EXTEM and FIBTEM assays [43], or in FIBTEM assay alone [28].
Among the four articles reporting data from EXTEM and FIBTEM only [30,34,35,37], EX-
TEM only [32], EXTEM and TEM-tPA only [40], and TEM-tPA only [39], an increased in the
“amplitude of the clot” was also a common finding.
Besides the increased clot amplitude, other abnormalities were interpreted as suggest-
ing a hypercoagulable state. First, a shortened CFT in EXTEM, INTEM, FIBTEM, and/or
HEPTEM was evidenced in 14 studies [26,27,31–33,38,41–46,49,50] out of 18, whereas
the others found no abnormalities or even a prolonged CFT [28,29,35,37]. Second, four
studies [32,38,39,50] out of five showed an increase in α angle in EXTEM or in TEM-tPA,
whereas the last reported a normal or even a decrease one [37].
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present early in the clinical 
course of the disease 
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1 IMW ↑ N N N-↑ ↑ N NP NP ↑ N N N N N N NP ↑ ↑ N NP NP 
  1 No difference between D0 and D10 (p > 0.05); 2 Normalization between D0 and D10 (p < 0.05); 3 Higher MCF in ICU patients than in IMW ones (p < 0.05); 4 Higher A(x) in ICU patients than in IMW ones
(p < 0.05); 5 Lower ML in patients with TE (p < 0.05); 6 Longer CT in patients with TE (p < 0.05); 7 Higher clot amplitude in COVID-19 patients upon admission (p < 0.0001); 8 Higher MCF in COVID-19 patients
upon admission (p < 0.0001); 9 Higher clot amplitude in COVID-19 patients upon admission (p < 0.05); 10 Higher MCF in COVID-19 patients upon admission (p < 0.05); 11 Shorter CFT in COVID-19 patients (p <
0.001); 12 Higher MCF in COVID-19 patients (p < 0.05); 13 Higher MCF with low dose of LMWH (p < 0.001); 14 Higher A(x) in patients with TE (p < 0.05); 15 Higher MCF in patients with TE (p < 0.05); 16 Shorter
CFT in patients with TE (p < 0.05). Results from the APTEM assay were only reported by one case report [26] and were consistent with the absence of hyperfibrinolysis. Results from the HEPTEAM assay were
reported by only four studies and are displayed apart [26,41,44,50]. Results from the investigator-modified assay derived from EXTEM assay to investigate potential hypofibrinolysis (TEM-tPA) were reported by
only two studies and are displayed apart [39,40]. Abbreviations: ICU: Intensive care unit (adults); IMW: Internal medicine ward; PICU: Pediatric intensive care unit; PW: Pediatric ward; TE: Thrombotic events; N:
Result within the reference range; ↑: Result above the reference range; ↓: Result below the reference range; N-↑: Result at the upper limit of the reference range; N-↓: Result at the lower limit of the reference
range; NP: Not provided; NA: Not assessed; tPA: tissue plasminogen activator.
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Table 6. Main findings of studies reporting results from the HEPTEM assay (ROTEM).
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Table 7. Main findings of studies reporting results from the TEM-tPA assay (ROTEM).
First author
(Country) Design n Ward Device Controls
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No clot lysis after 60 min in patients as
compared to healthy controls.
Resistance to clot lysis not only related
to high fibrinogen levels: dysregulation
of the fibrinolytic system?
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1 No difference between the two groups (p > 0.05); 2 Higher LI30 in COVID-19 patients (p < 0.05). Abbreviations: ICU: Intensive care unit (adults); IMW: Internal medicine ward; N: Result within the reference
range; ↑: Result above the reference range; ↓: Result below the reference range; NP: Not provided; NA: Not assessed; tPA: tissue plasminogen activator.
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Some articles also reported a reduced or absent fibrinolysis, better evidenced with
added plasminogen activator (tissue plasminogen activator, tPA) [39,40] than
without [26,30,32,34,37,42–44,46,48], whereas others did not report any
abnormality [27,31,35,45,46,50]. Few articles studied fibrinolysis over time and found
it persistently defective [26,29]. Fibrinolysis was weaker in ICU COVID-19 patients than
in non-ICU COVID-19 patients (p < 0.05 [32,39,48]), and among ICU patients in those
with SOFA score > 10 (p = 0.004 [29]) or with thrombotic events (p = 0.001 [44]). However,
there was no difference between ICU COVID-19 patients and ICU non COVID-19 patients
(p > 0.05 [32]).
Among the five studies comparing results from COVID-19 patients versus non-COVID-
19 (surgical or suffering from pneumonia or ARDS) patients [32,35,36,45,46], three reported
a hypercoagulable pattern only in COVID-19 patients (p < 0.05 [35,36,45]), a finding which
could be explained by a fibrinogen level remaining within the reference range for non-
COVID-19 patients [45]. The other two [32,46] showed a similar hypercoagulable pattern
in COVID-19 and non-COVID-19 patients as compared with healthy controls (p < 0.001),
however with a more pronounced one (p < 0.05) in COVID-19 patients despite a similar
fibrinogen level [46].
Among the five studies reporting data from COVID-19 adult patients both in an ICU
and an IMW [28,32,39,41,48], one showed a similar hypercoagulable profile (increased
maximum clot firmness) for both groups (p > 0.05 [48]), whereas the four others showed
a similar hypercoagulable pattern (increased “amplitude of the clot” or maximum clot
firmness with or without a decreased CFT) for both groups compared with healthy con-
trols or manufacturer’s reference range; however, the hypercoagulable pattern was more
pronounced for ICU patients (p < 0.05 between both groups).
Results reported in children [33] showed a hypercoagulable pattern comparable to
adults with an increased in MCF in INTEM, EXTEM, and FIBTEM assays and a slightly
decreased CFT.
Overall, the authors concluded from those described reports that COVID-19 pa-
tients exhibit a hypercoagulable profile characterized by an increased fibrinogen compo-
nent of clot mechanical strength reflected by an increase in clot amplitude (A(x)) and/or
maximum clot firmness (MCF), sometimes associated with a shorter clot formation time
CFT [26,27,31–33,38,41–46,49,50], or an increased α angle [32,38,39,50]. This pattern was
often associated with an impaired or absent fibrinolysis [26,30,32,34,37,39,40,42–44,46,48].
In summary, four points are worthy of consideration. First, the hypercoagulable profile
defined just above was observed early in the clinical course of the disease [41,50]. Second,
it was observed in both ICU and non-ICU COVID-19 patients [28,32,39,41,48]. Third, it
persisted over time from admission up to 10 to 14 days later [26,27,29,45]. Fourth, it was
observed even in the absence of heparin neutralization and despite higher therapeutic
intensity anticoagulation administration [26,47]. Of note, only six studies [28,33–35,44,49]
gathering 195 patients examined the potential association with thrombotic events occurring,
and only two [34,44] reported that patients with thromboembolic complications exhibited
low or even absent fibrinolysis.
3.5.2. TEG
A total of 403 patients, of whom 402 were COVID-19 ICU patients, had at least one
VET performed with TEG. Most of them were intubated and mechanically ventilated. They
almost all received anticoagulation by UFH or LMWH, at least at prophylactic dose.
Among the 15 TEG studies, two versions of the device were used: the TEG5000
(n = 7) [52–58] and the brand-new version TEG6s (n = 7) [59–65]. One article reported data
without specification of the device [51]. Results are summarized in Table 8.
Kaolin TEG with heparinase (CKH) was the most used assay, as heparin is neutralized,
and most patients received heparin. Among the 14 studies using this assay [51–60,62–65],
an increase in maximum clot amplitude was reported, but this finding needs to be tempered
for the following reasons. With patients’ values higher than reference [51,54,57,58,60] or
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locally established [52,53,56] values, MA was considered abnormally increased, while in
other studies MA was found at the upper limit of normal [59,62,64,65] or increased only
in certain patients [55,63]. For reaction time (R), 5 studies found decreased values from
reference ranges [57] or from healthy volunteers [52,53,55,58], 4 reported decreased kinetics
reaction K parameter as compared with healthy volunteers [52,53,55,58], and 11 reported
increased α angle as compared with reference ranges (42,45–48,52,53) or healthy volun-
teers [54,57–60,64,65]. Impaired fibrinolysis was found in eleven studies, with ‘fibrinolytic
activity’ at 30 min after maximum amplitude (LY30) reduced as compared with reference
ranges in healthy volunteers [52,53], or even undetectable [51,54,57–60,62–65].
TEG Functional Fibrinogen (CFF) was assessed in four studies [59,61,62,65], showing
an increase in maximum clot amplitude with a median CFF-MA ranging from 41 to 56 mm
for all patients as compared with manufacturer’s reference range (15 to 32 mm), and with a
negative skewness coefficient of −0.37 [59].
Increased fibrinogen component of clot strength was considered as the hallmark
of hypercoagulability, associated with at least one of the following: a shorter reaction
time R [52,53,55,57,58], a shorter kinetic time K [52,53,55,58], and an increased α an-
gle [52–60,64,65]. This pattern was often associated with an impaired [52,53] or absent
fibrinolysis [51,54,57–60,62–65].
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In summary, three points are worthy of attention. First, the hypercoagulable pattern
defined as just above was observed in both ICU and non-ICU COVID-19 patients [65].
Second, it was observed despite UFH or LMWH anticoagulation at prophylactic doses
or higher, and an anti-Xa activity within the target range without heparin neutralization
(TEG, CK assay) [49]; and third it persisted over time [53,59–61]. However, the association
between the observed pattern and the occurrence of thrombotic events remains a matter of
debate. One study including 21 patients reported that an increase in MA provides 100%
sensitivity and 100% negative predictive value to discriminate between patients with high
or low rate of thrombotic events (44), but only a few patients were reported. Another
study (44 patients) reported that no evidence of clot lysis at 30 min (LY30) associated with
high D-dimers levels (>2600 µg/L) could predict thromboembolic events (p = 0.008) and
need for hemodialysis in critically ill patients (p = 0.004) with COVID-19 [51]. However,
seven other studies [53,55,58–60,63,64] comprising 243 patients did not find an association
between the VET parameters and the occurrence of thrombotic events.
3.5.3. Quantra
The Quantra device was used in two studies [66,67], both prospective, one of them
comparing data from ICU non-COVID-19 patients with ICU COVID-19 patients [66]. The
two studies included 44 ARDS intubated and mechanically ventilated ICU patients, of
whom 33 were COVID-19 positive. All patients received anticoagulation according to
local protocols or guidelines [74]. Tests were performed using the QPlus Cartridge, which
contains heparinase in the CTH channel and polybrene in the CS and FCS channels to
neutralize heparin. Results are summarized in Table 9.
Both studies suggested a hypercoagulable pattern associated with preserved thrombin
generation, assessed by prothrombin fragments 1 + 2 and thrombin–antithrombin complex
levels [66] and despite UFH or LMWH anticoagulation at a minimum of prophylactic
dosing. However, the VET hypercoagulable pattern tended to normalize [67] after a
50% increase in thromboprophylaxis dosing and based on the body weight. However,
the association between the documented hypercoagulable pattern and thrombotic event
occurrence was not studied.
3.5.4. ClotPro
ClotPro was used in a retrospective study in Austria [24] and in three cases in Hun-
gary [68] of ICU patients who received anticoagulation at prophylactic doses or greater.
VET assays were performed using four reagents and channels (Table A7), namely EX-test,
IN-test, Fib-test, and tPA-test. Results are summarized in Table 10.
Results from the tPA-test showed a hypercoagulable pattern (increased maximum
clot firmness) associated with impaired fibrinolysis; the latter was assessed either by a
decreased lysis capacity of the clot in presence of tPA as compared with manufacturer’s
reference values, followed few days later by a normalization with still marked elevated
D-dimers levels [68], or by an increased clot lysis time as compared with healthy controls
with a p-value < 0.01 [24]. However, these findings do not appear to be associated with the
occurrence of thrombotic events [24].
J. Clin. Med. 2021, 10, 1740 38 of 56

























































N N N N ↑ ↑ Significant increase in procoagulants
leading to a pronounced imbalance between
procoagulants and anticoagulants, and a
subsequent uncontrolled thrombin























N 3 NP NP
↑ ↑ ↑
Procoagulant profile with a trend to





N 4 ↑ 4 N 4
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Abbreviations: ICU: Intensive care unit (adults); ARDS: Acute respiratory distress syndrome; N: Result within the reference range; ↑: Result above the reference range; NP: Not provided; NA: Not assessed.
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J. Clin. Med. 2021, 10, 1740 40 of 56
4. Discussion
Although all of the studies share the common viscoelastometric testing concept in
evaluating COVID 19 patients’ hemostasis, the differences in the testing systems and
reagents, resultant data and implications, and variability of the patients’ severity of illness
make interpretation difficult. The association with thrombotic events is not very well
established, and might largely depend on the actual VET used. We will more specifically
discuss whether VETs provide clinically relevant information about fibrinogen in a COVID-
19 patient, and we will discuss its use regarding potential anticoagulation with heparins.
4.1. Methodological Issues in VET Studies
There are numerous methodological differences among the 44 studies using VETs to
assess the hemostasis in COVID-19 patients we have retrieved and analyzed, explaining
why results were not consistent through studies, or sometimes even conflicting. This was
already raised by previously published reviews [70,71].
First, the design was heterogeneous among studies with 19 prospective studies [28–
32,39–46,52,59–61,66,67], 19 retrospective ones [24,27,33–36,47–49,51,53–58,62–64], and 6
case reports [26,37,38,50,65,68] with no randomized controlled trial (VET versus no VET).
Studies also differed on the timing of the sampling for VET assay (ranging from admis-
sion [27,29–31,36–38,44–46,50,53,56,66] to a median of 18 (13–29) days after admission [47]),
the number of studied patients (ranging from 5 excepted case-reports [40,54] to 64 [58]), the
anticoagulation regimen, and the diagnosis of thrombotic events (solely based upon clinical
signs, based upon a systematic screening by imaging or based upon clinical signs and con-
firmed by imaging). There is variability how the authors defined hypercoagulable patterns
in VETs based on the parameters used and the reference values considered. Some studies
used reference range from local healthy subjects [24,28,31–33,39–41,46,47,50,52,53,55,56],
while most of the reference values were manufacturer determined and could not be fully
adapted to the local population and settings [1,3].
Second, there was also heterogeneity among the patients’ characteristics concerning
age, severity of the disease, gender distribution, and comorbidities. In addition to the lack
of power to evidence a statistically significant association between the VET patterns and
thrombotic events, this heterogeneity could explain the differences between the studies’
results, at least in part.
One important consideration is different monitoring devices were used. Even though
they share the same objective of viscoelastic clot properties evaluation, they present sub-
stantial differences from technological and methodological viewpoints. First, they rely on
different technologies to monitor clot formation, clot strength, and clot lysis (i.e., thromboe-
lastometry, thromboelastography, and sonorheometry). Second, there are some differences
in the way the tests are carried out and the sample and reagents are delivered to perform
the assay, specifically the activators. While in the most recent versions of the instruments
(TEG6s, ROTEM sigma, Quantra, ClotPro) the reagents are already included in reaction
cartridges or in tips and require only the addition of the blood sample, the previous
versions (ROTEM gamma and delta, TEG5000) required manual or semi-automated pipet-
ting of reagents and samples, resulting in very high inter- and intra-operator coefficients
of variation for some parameters [77,78]. Third, the composition of the reagents differs
from one manufacturer to another, especially for the assay aiming to assess the fibrino-
gen component of clot strength, also called functional fibrinogen. Briefly, clot strength is
mainly due to the interaction between fibrin network (containing activated factor XIII),
platelets [7], neutrophil extracellular traps [79], and red blood cells [80,81]. Platelets are an
important contributor to the clot strength, and the MA (TEG), MCF (ROTEM and ClotPro),
and CS (Quantra) parameters reflect both platelet count and function [9,82], as well as
fibrin contribution. To assess functional fibrinogen, platelet contribution must be inhibited,
and two different approaches are used that include abciximab (GpIIb-IIIa inhibitor, TEG
and Quantra), cytochalasin D (cytoskeleton inhibitor, ROTEM), or a combination of both
(ClotPro). Some studies [83–85] compared the fibrinogen contribution to clot mechanical
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strength measured with VET using either a GpIIb-IIIa inhibitor or cytochalasin D and
showed that the latter was more efficient: functional fibrinogen assessment with TEG or
Quantra could lead to an overestimation of fibrinogen levels as compared with ROTEM.
However, cytochalasin D alone may not completely remove the platelet contribution,
especially with a high platelet count, and a combination of a GpIIb-IIIa inhibitor and
cytochalasin D seems to provide more accurate results [83–85].
Therefore, we can reasonably doubt that the results obtained from the different de-
vices and studies are interchangeable, as previously noted in non-COVID-19 patients [3,86].
There may even be differences in results between different versions of the same device (as
between ROTEM-delta and ROTEM-sigma for example [15,87], or between TEG5000 and
TEGS6s [17–19]), but overall the devices show good correlations for the main parameters
evaluated [14,86,88,89]. To our knowledge, there have not been previous comparisons in
COVID-19 patients. Studies on VET have always been plagued by those issues, unfortu-
nately still unresolved.
4.2. Definition of a Hypercoagulable State by VET and Association with Thrombotic Events
The conventional clotting time corresponds to the ‘reaction time’ R for TEG, and the
‘clotting time’ CT for ROTEM, ClotPro, and Quantra. Extended fibrin polymerization is
described as the kinetics time K and α angle for TEG and CFT and α angle for ROTEM and
ClotPro. The clot strength is defined as maximal mechanical strength (maximal amplitude
MA for TEG, maximal clot firmness MCF for ROTEM and ClotPro, and clot stiffness CS for
Quantra).
Beyond a purely biological definition, for which there is no consensus or appropriate
term, sometimes ‘procoagulant’ or hypercoagulable, what matters is the association with
the patient’s thrombotic risk. Outside the COVID-19 setting, two systematic reviews and
a subsequent meta-analysis involving 1285 patients with solid tumors or hematopoietic
malignancies [90] or 8944 surgical patients [91] showed that the occurrence of thrombotic
events was associated with features consistent with hypercoagulability: acceleration of
fibrin polymerization (increase in α angle in both ROTEM and TEG, shortened CFT in
ROTEM and shortened K time in TEG) and increased clot mechanical strength (increase in
MCF for ROTEM and in MA for TEG). However, another meta-analysis of 1081 patients
in a variety of clinical settings [92] showed that ROTEM and TEG had a moderate ability
to discriminate between patients who developed a thrombotic event and those who did
not, with a diagnostic odds-ratio of 3.6, a low sensitivity (56%) but a somewhat better
specificity (76%). It is noteworthy that the performance in the prediction of thrombotic
events depends both on the type of device (with a better performance for ROTEM with
a diagnostic odds-ratio of 6.3 against 3.2 for TEG), and on the type of thrombotic event
(with a sensitivity of 67%, a specificity of 72%, and a diagnostic odds-ratio of 6.4 for arterial
thrombotic events, contrasting with a sensitivity of 41%, a specificity of 70%, and an odds-
ratio diagnosis of 3.1 for venous thrombotic events). Why VET findings should be more
associated with arterial thrombotic events than with venous ones is obscure, though.
Regarding the 44 studies we examined, all authors concluded that COVID-19 pa-
tients displayed a hypercoagulable pattern characterized by an increased clot mechanical
strength (assessed by CS in Quantra, MA in TEG and MCF in ROTEM and ClotPro) basi-
cally due to an excessive fibrin(ogen) component (assessed by FCS in Quantra, CFF-MA
in TEG, FIBTEM-MCF in ROTEM and MCF from FIB-test in ClotPro), associated with a
shortening of clot initiation (decreased K in TEG and CFT in ROTEM and ClotPro) in 18
studies [26,27,31–33,38,41–46,49,50,52,53,55,58], an acceleration of fibrin polymerization
(increased α angle in TEG, ROTEM and ClotPro) in 15 studies [32,38,39,50,52–60,64,65], and
an impaired or reduced fibrinolysis in 26 studies [24,26,30,32,34,37,39,40,42–44,46,48,51–
54,57–60,62–65,68]. It is crucial to note however that an association between that pattern
and thrombotic events was evidenced by only one study [56] out of the sixteen addressing
the issue [24,31,33–35,44,49,51,53,55,56,58–60,63,64]: an increase in the maximum clot am-
plitude (MA) provides 100% sensitivity and 100% negative predictive value to discriminate
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between patients with a high or low rate of thrombotic events, but confidence intervals
were not reported [56]. This raises doubts about the clinical significance of the ‘so called’
hypercoagulability identified by VET and its potential clinical implications (e.g., thrombotic
risk stratification or adjustment of thromboprophylaxis).
4.3. Ability of VETs to Detect Hypofibrinolysis State and Association with Thrombotic Events
Fibrinolysis is monitored at a specific time x minutes after MA was reached for TEG
(LY(x) parameter), and by maximal lysis ML (reduction in clot firmness after MCF in relation
to MCF) or lysis of the clot at a given time x minutes after CT was reached (LI(x)) parameter
for ROTEM and ClotPro. The diminution in clot maximum amplitude was thought to be
due to both fibrinolysis and potentially platelet-mediated clot retraction [4–6,93]. However,
as no change in clot mechanical strength after the maximum was reached was reported
in many studies in COVID-19 patients, platelet-mediated clot retraction does not seem to
play a significant role here.
Usually VETs are used to detect major hyperfibrinolytic states [94] that occur in the
most severe, advanced stages of hemostasis derangements in clinical settings such as
trauma and perioperative hemorrhage. However, could they be used to assess hypofib-
rinolysis? VETs have shown potential usefulness in sepsis-induced coagulopathy [10]
and trauma-induced coagulopathy [11] to detect low levels of fibrinolysis and to identify
patients for whom the administration of tranexamic acid should be avoided. Endogenous
systemic fibrinolysis is usually weak because of low or even no circulating levels of free
plasminogen activators, which are fully complexed to PAI-1 and thus inactive. Normal
lysis of a whole blood clot is therefore a slow phenomenon [95], and its visualization on a
VET trace recorded during one hour or two seems unlikely. Furthermore, as the zero value
belongs to the manufacturer’s reference range, speaking about a reduced or an absent
fibrinolysis seems awkward if there is no control group for comparison. Among the 25
studies reporting a reduced or absent fibrinolysis, only 8 [24,32,39,40,44,48,52,53] made
this assessment by comparison with a control group.
Several ROTEM and TEG modifications have been reported adding urokinase plas-
minogen activator (uPA) or tissue plasminogen activator (tPA) to demonstrate hypofib-
rinolysis. A brief literature search revealed multiple protocols for modified ROTEM and
TEG including addition of a plasminogen activator. Although they show evidence of
hypofibrinolysis in different clinical settings, they all share the same methodological issues
and limitations. First, there is a lack of standardization concerning tissue factor concen-
trations, as low levels added to the sample produce non-reproducible results and often
a weak clot [96,97]. Second, there is also a lack of standardization in tPA concentrations
studied ranging from 50 to 625 ng/mL [96–98], and similar results for modified VET with
uPA [99,100], with an ‘optimal concentration of uPA’ differing from subject to subject, and
a wide interindividual variation in lysis parameters [99].
Among the 44 studies analyzed in this review, only four investigated the effect of
adding tPA to standard VET. Two used the ClotPro device [24,68] and its ready-to-use
tPA-test reagents, which are now CE-marked, whereas the two others [39,40] used an
in-house ROTEM assay with two different tPA concentrations (named TEM-tPA), making a
comparison between them problematic. No study has investigated a defective fibrinolysis
using the Quantra device into the COVID-19 context, whereas a new dedicated reagent
cartridge is now available [23]. The four articles share the same conclusion that increased
clot maximum amplitude and decreased lysis index reflect an increase in clot strength and
a decreased fibrinolytic capacity, results that need to be confirmed with a larger cohort.
Further, the TEM-tPA assay needs to be standardized and validated [101], although it
seemed to show good intra- and inter-assay precision in healthy controls [39].
Association between impaired fibrinolysis assessed with VETs and clinical outcomes
is a matter of debate. Some studies failed to find an association [24,53,55,58,59], while
others suggested that impaired fibrinolysis was associated with a higher rate [34] and a
shorter time to the occurrence of thrombotic events [51], and together with D-dimer levels
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it could predict thrombotic events [44,51] and the need for hemodialysis in critically ill
patients with COVID-19 [51].
4.4. Correlation between Clauss Fibrinogen and Functional Fibrinogen Assessed by VETs
Outside of the COVID-19 context, the ROTEM FIBTEM is the most studied point
of care fibrinogen level assay with numerous studies in trauma, cardiac surgery, liver
transplantation, and obstetrics. The correlation between Clauss fibrinogen and FIBTEM-
MCF or fibrinogen-related TEG parameters was reported as variable with R2 values ranging
from 0.44 to 0.94 for ROTEM [102] and from 0 [103] to at least 0.80 [102] for TEG. The
clinical experience with the Quantra device is limited, with only few published studies
to date, but the correlation between Clauss fibrinogen and FCS ranged from moderate
to very good, with R2 values ranging from 0.55 to 0.88, with a huge variability between
studies [14,22,104,105]. To our knowledge, data concerning correlation between Clauss
fibrinogen and clot amplitude and maximum clot firmness provided by the ClotPro FIB-test
assay is not yet available.
Among the 44 studies dealing with VETs and COVID-19 patients, only a few
ones [33,41,53,58] investigated the correlation between Clauss fibrinogen and ‘functional
fibrinogen’ assessed by VETs. For ROTEM®(FIBTEM), one report noted a good correla-
tion (Pearson’s correlation coefficient r = 0.84) [41], while another showed no correlation
(p = 0.130) in children [33]. Two studies explored TEG in this regard and reported a moder-
ate to good association (Pearson’s correlation coefficient r = 0.453 [58] and 0.74 [53]). These
limited results due to low COVID-19 patient numbers and different assays suggest more
studies are required.
Further, whether VET characteristics are unique to hyperfibrinogenemia alone is an
important question, as almost all COVID-19 patients also present with hyperfibrinogenemia.
Patients with hyperfibrinogenemia may exhibit a ‘functional fibrinogen’ (VET parameter)
in the reference range [35,37,66], while other reports of fibrinogen levels within reference
ranges exhibit increased functional fibrinogen [26,28,48].
The authors of a previously published review [69] highlighted the potential usefulness
of VET in accurately assessing plasma fibrinogen levels in COVID-19 patients receiving
direct thrombin inhibitors (DTI) through the assessment of the clot amplitude of the
functional fibrinogen assay. Indeed, evaluation of fibrinogen levels by the Clauss method
could lead to an underestimation due to the inhibition of the thrombin included in the
reagent by the DTI [106,107], ranging from 23 to 96% according to the reagent used [107].
4.5. Impact of Differences in Anticoagulation Regimens (Type (UFH, LMWH) and Dosage)
Most currently studied COVID-19 patients receive heparin (LMWH or UFH), ei-
ther with prophylactic or therapeutic regimens according to local protocol or guide-
lines [74–76,108]. Some studies specifically noted when blood samples for VETs were
drawn in heparinized patients, but the timing of administration was often missing as well
as anti-Xa levels. While for TEG, heparinase reagents were frequently used (14 studies of
15 [51–60,62–65]), this was not the case for ROTEM: only a few ones (4 of 25) generated
data with HEPTEM assay, together with INTEM assay. Among these four latter studies,
only one [26] reported different results from the two assays, whereas the three others
showed similar results with both assays [41,44,50]. This raises questions that include (i)
the effect of heparin, particularly at low doses, on VET results, (ii) whether heparinase or
polybrene added to heparinized blood completely neutralized circulating heparin, and (iii)
whether VETs can be used to guide heparin therapy. These questions were not raised by
the previously published reviews [69–72].
The effect of heparin (UFH and LMWH) on VETs (performed without heparin neu-
tralization) seems, according to the literature, to depend mainly on the heparin dose and
the VETs used. Two trends have emerged for prophylactic or therapeutic concentrations
(anti-Xa up to 1.5 IU/mL). First, with TEG, anti-Xa levels and R and K parameters (clot
initiation) seemed to correlate, while an inverse correlation between anti-Xa levels and α
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angle and MA is observed (fibrin polymerization), sometimes leading to a ‘flat line’ with
the highest anti-Xa levels [109–112]. Second, fewer data are available for ROTEM, but there
seems to be a correlation only between anti-Xa levels and CT parameter from the INTEM
assay (clot initiation) [112–114].
In the setting of cardiac surgery with cardiopulmonary bypass, VETs have been in-
creasingly used, and manufacturers have adapted testing to neutralize circulating heparin
by the addition of heparinase or polybrene in order to differentiate between insufficient
heparin neutralization in patients with protamine from underlying post-bypass coagulopa-
thy. Few data are available, however, on whether this neutralization is complete. In an
in vitro study performed with TEG and coated cups with heparinase [109], results were
similar between native samples and samples spiked with heparin (UFH or LMWH) or
danaparoid, but tested concentrations were too low (0.005 to 0.05 IU/mL) to be clinically
relevant. Another in vitro study performed with ROTEM and heparinase [113] showed
similar results between native samples and samples spiked with increasing heparin (HNF)
concentrations ranging from 0.1 to 1 IU/mL.
Among the 44 COVID studies we retrieved, several mentioned a considerably high
incidence of thrombotic events despite thromboprophylaxis, in line with most reports,
and raising the potential interest of increasing anticoagulant doses. Could VETs then be
useful to identify patients who will benefit from a higher dose of thrombosis anticoagulant
prophylaxis? This remains a matter of debate. According to the authors, VETs seem able to
detect coagulation abnormalities advocating for a hypercoagulable prothrombotic state
in a broad sense, including procoagulable state (with a decreased clot formation time),
hypercoagulable state (with an increased clot strength), and impaired fibrinolysis (with a
reduced or absent clot lysis) early in the course of the disease, and even if conventional
coagulation tests remain in the reference ranges. Second, as reduced or absent fibrinolysis
was associated with an increased risk of thrombotic events outcome despite anticoagula-
tion [34,42–44,51,54,57,63,64], we could assume that VET results might be used to adapt
level of anticoagulation. Five studies [26,47,59,61,67] have reported VET parameters from
ICU COVID-19 patients before and after an intensification of thromboprophylaxis, but
results were inconsistent. Two of them showed a decrease in clot mechanical strength and
in functional fibrinogen level [47,67], and even in the rate of thrombotic events [47], and
the three others [26,59,61] did not find any significant difference. However, if VETs still
demonstrate a hypercoagulable pattern despite anticoagulation at least with a prophy-
lactic dose and even an anti-Xa level within the target range [60,61], it was not always
associated with thrombotic outcomes, although there was no systematic VTE screening
either [28,35,58,63]. Third, three studies have shown an exaggerated thrombin generation
despite anticoagulation, at least with a prophylactic dose [39,48,66], advocating for a new
way to monitor efficiency of thromboprophylaxis.
Rather than VETs, the study of thrombin generation could be more interesting to
adjust anticoagulant therapy as heparin inhibits thrombin generation by multiple path-
ways as reviewed elsewhere [115]. Several methods exist to study thrombin generation,
either with biomarkers such as prothrombin fragment 1 + 2 or thrombin–antithrombin
complexes [116] (thrombin generation in vivo), or in vitro by assessment of the levels of
thrombin over time (through the use of a chromogenic or fluorogenic substrate) in response
to initiation of coagulation. Regarding the latter, several commercial devices and assays are
available [117,118]. Of note, thrombin generation assays (TGAs) are highly sensitive to pre-
analytical aspects [119]. So far, some in vitro studies have reported that there was a heparin
concentration dependent decrease in thrombin generation [120,121]. Studies showed that
COVID-19 patients had a higher endogenous thrombin potential [31,39,48,66,122–127] than
manufacturer’s reference range, healthy controls or patients with sepsis, sometimes despite
UFH or LMWH anticoagulation at a minimum of prophylactic dosing. Few studies found
a heparin dose-dependent decrease in thrombin generation [125,127] as described in vitro.
Interestingly, one study showed that a persisting thrombin burst despite anticoagulation
correlated with non-survival [123], whereas another found no difference between noncriti-
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cal and critically ill COVID-19 patients [124]. Further studies are needed to evaluate the
clinical value in this context of the in vitro study of thrombin generation, and particularly
with the new automated ST Genesia device [118], as already mentioned elsewhere [128].
A potential issue could be the non-availability of such device and the high turn-around-time
for a result There is also an unmet need regarding the exploration of fibrin polymerization
and lysis [95] with good and convenient assays.
4.6. Summary of the Conclusions of the Previously Published Reviews
Conclusions of the previously published reviews are summarized in Table 11. Overall,
the four reviews reported the same findings as we do: COVID-19 patients displayed
an abnormal VET pattern [69–72], but further studies are needed for various reasons.
Moreover, we challenge the idea that such a pattern represents hypercoagulability; one
main reason is that inhibitory systems are not at all taken into account, in sharp contrast
with TGAs.
Of note, except the systematic review about the potential usefulness of TEG [71], no
consistent association between the abnormal VET pattern and clinical outcome could have
been demonstrated. Interestingly, one review [69] pointed out the potential usefulness of
VETs in accurately assessing plasma fibrinogen levels in COVID-19 patients receiving DTI
(see Section 4.4).
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Table 11. Conclusions of the previously published reviews.
First Author (VET Devices) Type of the Review Aim of the Review Number and Type of Studies Included Conclusions of the Authors
Görlinger et al. [69]





as well as highlight of
what we still do not know
about COVID-19
associated coagulopathy
8 studies (5 prospective, 3 retrospective)
VETs can detect the presence of hypercoagulability in
critically ill COVID-19 patients, but further studies
are needed to define the role of viscoelastometric
testing in the management of patients
VETs can be used to assess fibrinogen levels of
COVID-19 patients receiving direct thrombin
inhibitors (such as argatroban and bivalirudin)
through functional fibrinogen measurement
Tsantes et al. [70]
(ROTEM, TEG and Quantra) Narrative review
Evaluation of the
usefulness of VETs in
clinical practice to guide
anticoagulant treatments
or predict prognosis
13 studies (8 prospective, 5 retrospective)
VETs can detect the presence of hypercoagulability in
critically ill COVID-19 patients, but further studies
are needed to establish reference ranges for each
viscoelastic test, to define the common cut-off values
of hypo- and hypercoagulability or threshold values
to predict prognosis, or to guide anticoagulant,
antiplatelet or fibrinolytic therapy
Hartmann et al. [71]
(TEG) Systematic review
Evaluation of the
usefulness of TEG in




15 studies (5 prospective, 9 retrospective and
one case report)
TEG can detect a hypercoagulable state in patients
with COVID-19, and provides differential diagnostic
insights alongside the ability to risk-stratify patients
at elevated risk for complications such as VTE or
kidney failure
Further studies are needed to elucidate the optimal
use of TEG to maximize patient benefit
Słomka et al. [72]
(ROTEM and TEG) Systematic review
Evaluation of the
performance of TEG and




10 studies (2 prospective, 8 retrospective)
VETs can detect a hypercoagulable state and
fibrinolysis shutdown in COVID-19 patients, and
might be used to identify patients with high
prothrombotic risk for whom an antithrombotic
therapy would be benefic
J. Clin. Med. 2021, 10, 1740 47 of 56
5. Conclusions
VETs are now well established in acute settings to assist in bleeding management and
transfusion practices, with convenient, fully automated devices and ready-to-use reagents.
Since the beginning of the pandemic, they were used to characterize hemostasis abnormali-
ties in critically ill COVID-19 patients. As already reported in previous reviews [69–72],
almost all the studies we analyzed reported increased clot strength, considered to be a
hallmark of the ‘hypercoagulable state’, often associated with impaired fibrinolysis (with
the analytical limitations we have emphasized)—globally referred to as ‘prothrombotic
pattern’, but there was no consistent association with clinical outcomes. Indeed, few studies
suggested an association with the occurrence of thrombotic events, as well as with the need
for hemodialysis [34,44,51,56]. However, lack of power (low number of studied patients),
retrospective design, and no standardized study protocol are of concern.
In the COVID-19 setting, the appraisal of (high) fibrinogen levels through VET as
opposed to the Clauss method in the laboratory is not an obvious asset. As already pointed
out however [69], VET could be of interest for accurately assessing plasma fibrinogen levels
in COVID-19 patients receiving DTI through the assessment of the clot amplitude in func-
tional fibrinogen assay. Modified VETs (with addition of a plasminogen activator) to detect,
quantify, and monitor hypofibrinolysis in whole blood (with the advantage for instance to
integrate the PAI-1 released by platelets) could be of clinical relevance [24,39,40,68].
Three different types of studies would be needed. First, prospective ones comparing
the results from the different available devices are needed. Second, as it was already
highlighted by previously published reviews [69–72], further prospective studies are
needed, ideally randomized, to highlight the added-value of VET in predicting the clinical
course of the disease, addressing patients to the appropriate ward according to their risk
stratification, and identifying which patients would benefit from intensified anticoagulant
treatment and those who would show clot resistance to fibrinolysis. Third, prospective
randomized controlled trials are needed to evaluate the usefulness of VET and TGA in
monitoring and adapting thromboprophylaxis.
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Appendix A. ROTEM®Reagents and Parameters
Table A1. ROTEM®reagents.
Assay Reagent Description Heparin Neutralization
INTEM Ellagic acid Intrinsic pathway screening test No
HEPTEM Ellagic acid + Heparinase Intrinsic pathway screening test withheparinase Yes
1
EXTEM Tissue factor + Polybrene Rapid overview of the coagulationprocess Yes
2
APTEM Tissue factor + Aprotinin + Polybrene Exploration of the fibrinolysis bycomparison with the EXTEM results Yes
2
FIBTEM Tissue factor + Cytochalasin D + Polybrene
Functional detection of the fibrinogen
level after platelet inhibition by
cytochalasin D
Yes 2
1 Up to 7 IU/mL according to the manufacturer; 2 Up to 5 IU/mL according to the manufacturer.
Table A2. ROTEM®parameters.
Parameter Description
CT (s) Clotting time: time interval from the start of the run until a 2 mm clot forms
CFT (s) Clot formation time: time interval from CT until a clot amplitude of 20 mm is reached
α angle (◦) Rate of clot formation
A(x) (mm) Amplitude of the oscillation due to clotting x minutes after CT
MCF (mm) Maximum clot firmness: maximum clot amplitude
LI(x) (%) Clot lysis index: ratio between MCF and amplitude of the clot x minutes after CT
ML (%) Maximum lysis: maximum fibrinolysis detected during the observation period, expressed as a percentage of MCF
Appendix B. TEG®Reagents and Parameters (Haemonetics Corporation,
Boston, MA, USA)
Table A3. TEG®reagents.
Assay Reagents for TEG5000 Reagents for TEG6s Description HeparinNeutralization
RapidTEG (CRT)
Tissue factor + Kaolin +
Heparinase if heparinase
cups are used
Tissue factor + Kaolin Rapid overview of thecoagulation process
Yes (if heparinase cups
were used for
TEG5000), otherwise no

























R (min) Reaction time: time to initial fibrin formation
K (min) Kinetics time: time to clot formation
α angle (◦) Rate of clot formation
MA (mm) Maximum amplitude: absolute clot strength
LY30 (%) Fibrinolytic activity 30 min after maximum amplitude was reached
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Appendix C. Quantra®Reagents and Parameters (HemoSonics, LLC, Charlottesville,
VA, USA)
Table A5. Quantra®QPlus cartridge and parameters.
Parameter Reagents Description Heparin Neutralization Manufacturer’sReference Range
CT (s) Kaolin (channel 1) Clotting time afteraddition of kaolin No 113–164 s






None, calculated as the
ratio of CT (channel 1)
over CTH (channel 2)
Clot time ratio NA 1 <1.4











None, calculated as the
difference between CS
(channel 3) and FCS
(channel 4)
Platelet contribution to
clot stiffness Yes 11.9–29.8 hPa
1 NA: not applicable.
Table A6. Quantra®QStat cartridge and parameters.
Parameter Reagents Description Heparin Neutralization Manufacturer’sReference Range
CT (s) Kaolin Clotting time afteraddition of kaolin No 113–164 s
CS (hPA) Thromboplastin + Polybrene Clot stiffness Yes 13–33.2 hPa
CSL (%)
None, calculated as the
normalized difference
between the clot stiffness
change after maximum clot
stiffness in the absence of
tranexamic acid and the
corresponding clot stiffness
change in the presence of
tranexamic acid
Clot stability to lysis Yes 93–100%
FCS (hPA) Thromboplastin +Abciximab + Polybrene
Fibrinogen contribution





None, calculated as the
difference between CS and
FCS
Platelet contribution to
clot stiffness Yes 11.9–29.8 hPa
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Appendix D. ClotPro®Reagents and Parameters (enicor GmbH, Munich, Germany)
Table A7. ClotPro®reagents.
Assay Reagent Description Heparin Neutralization
IN-test Ellagic acid Intrinsic pathway screeningtest No
HI-test Ellagic acid + Heparinase Intrinsic pathway screeningtest with heparinase Yes
EX-test Recombinant tissue factor +Polybrene
Rapid overview of the
coagulation process Yes
AP-test Tissue factor + Aprotinin +Polybrene
Exploration of the fibrinolysis
by comparison with the
EX-test results
Yes
tPA-test Recombinant tissue factor +Recombinant tPA + Polybrene
Exploration of the fibrinolysis




Recombinant tissue factor +
Cytolochalasin D + Abciximab
+ Polybrene
Functional detection of the
fibrinogen level after dual
platelet inhibition by
cytochalasin D and abciximab
Yes
RVV-test Reagent derived from Russellviper venom
Detection of factor Xa
inhibitors (LMWH, DOAC) No
ECA-test Ecarin + Polybrene Detection of direct thrombinantagonists Yes
NA-test None
Non-activated test for the
exploration of non-activated
coagulation in citrated blood
No
Abbreviations: LMWH: Low molecular weight heparin; UFH: unfractionated heparin; DOAC: Direct oral anticoagulant.
Table A8. ClotPro®parameters.
Parameter Description
CT (s) Clotting time: time interval from the start of the run until a 2 mm amplitude of oscillations due to clotting wasreached
CFT (s) Clot formation time: time interval from CT until a clot amplitude of 20 mm is reached
A(x) (mm) Amplitude of the oscillation due to clotting x minutes after CT
MCF (mm) Maximum clot firmness: maximum clot amplitude
ML (%) Maximum lysis: maximum fibrinolysis detected during the observation period, expressed as a percentage of MCF
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